|
gptkbp:instanceOf
|
antiviral drug
|
|
gptkbp:approvalYear
|
1982
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J05AB01
|
|
gptkbp:bioavailability
|
10-20% (oral)
|
|
gptkbp:brand
|
gptkb:Sitavig
gptkb:Zovirax
|
|
gptkbp:CASNumber
|
59277-89-3
|
|
gptkbp:category
|
antiviral drug
purine analogue
|
|
gptkbp:chemicalFormula
|
C8H11N5O3
|
|
gptkbp:contraindication
|
hypersensitivity to acyclovir
|
|
gptkbp:developedBy
|
gptkb:Burroughs_Wellcome
|
|
gptkbp:discoveredBy
|
gptkb:Howard_Schaeffer
|
|
gptkbp:eliminationHalfLife
|
2-3 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:firstSynthesized
|
1974
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Acyclovir
|
|
gptkbp:KEGGID
|
gptkb:D00222
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits viral DNA polymerase
|
|
gptkbp:MedlinePlusID
|
a682733
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
225.21 g/mol
|
|
gptkbp:patentExpired
|
yes
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:prodrugOf
|
aciclovir triphosphate
|
|
gptkbp:PubChem_CID
|
gptkb:DB00787
gptkb:CHEMBL135
2022
|
|
gptkbp:relatedTo
|
gptkb:famciclovir
gptkb:valacyclovir
gptkb:ganciclovir
|
|
gptkbp:routeOfAdministration
|
oral
topical
intravenous
|
|
gptkbp:RxNormID
|
1977
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
headache
renal dysfunction
|
|
gptkbp:UNII
|
3636Z1OQ0E
|
|
gptkbp:usedFor
|
gptkb:chickenpox
shingles
genital herpes
herpes simplex virus infection
herpes zoster
varicella zoster virus infection
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:Antiviral
|
|
gptkbp:bfsLayer
|
6
|